Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation

Viral Immunology

Volumn 25, Issue 5, 2012, Pages 379-386

  Kanda, Tatsuo ^a   Wu, Shuang ^a   Kiyohara, Tomoko ^b   Nakamoto, Shingo ^a   Jiang, Xia ^a   Miyamura, Tatsuo ^a   Imazeki, Fumio ^a   Ishii, Koji ^b   Wakita, Takaji ^b   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29;

ANIMAL CELL; ARTICLE; DRUG EFFECT; HEPATITIS A VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PROTEIN EXPRESSION; RIBOSOME; VIRAL CLEARANCE; VIRUS REPLICATION;

5' UNTRANSLATED REGIONS; AMANTADINE; ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HEPATITIS A VIRUS; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; PROTEIN BIOSYNTHESIS; RIBOSOMES; VIRUS REPLICATION;

HEPATITIS A VIRUS; HEPATITIS C VIRUS;

EID: 84867195272     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0021     Document Type: Article

References (49)

1. Bacon BR, and Khalid O: New therapies for hepatitis C virus infection. Mo Med 2011;108:255-259.
2. Balvay L, Soto Rifo R, Ricci EP, Decimo D, and Ohlmann T: Structural and functional diversity of viral IRESes. Biochim Biophys Acta 2009;1789:542-557.
3. Basu A, Meyer K, Lai KK, et al.: Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006;349:347-358.
4. Cordes S, Kusov Y, Heise T, and Gauss-Muller V: La autoantigen suppresses IRES-dependent translation of the hepatitis A virus. Biochem Biophys Res Commun 2008;368: 1014-1019.
5. Diegelmann J, Beigel F, Zitzmann K, et al.: Comparative analysis of the lambda-interferons IL-28A and IL-29 regulating their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 2010;5:e1522.
6. Doyle SE, Schreckhise H, Khuu-Duong K, et al.: Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44: 896-906.
7. Dunn C, Peppa D, Khanna P, et al.: Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-1300.
8. Fujiwara K, Kojima H, Yonemitsu Y, et al.: Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities. Liver Int 2009;29:838-845.
9. Gauss-Muller V, and Kusov YY: Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J Gen Virol 2002;83:183-192.
10. Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
11. Glass MJ, Jia XY, and Summers DF: Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5' noncoding region. Virology 1993;193:842-852.
12. Glass MJ, and Summers DF: Identification of a trans-acting activity from liver that stimulates hepatitis A virus translation in vivo. Virology 1993;193:1047-1050.
13. Ito T, Tahara SM, and Lai MM: The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J Virol 1998;72:8789-8796.
14. Kanda T, Basu A, Steele R, et al.: Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol 2006;80:4633-4639.
15. Kanda T, Imazeki F, Nakamoto S, Okitsu K, Fujiwara K, and Yokosuka O: Internal ribosomal entry-site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine. Hepatol Res 2010;40:415-423.
16. Kanda T, Imazeki F, and Yokosuka O: New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;4:548-561.
17. Kanda T, Jeong SH, Imazeki F, Fujiwara K, and Yokosuka O: Analysis of 5' nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities. PLoS One 2010;5:e15139.
18. Kanda T, Steele R, Ray R, and Ray RB: Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol 2007;81: 669-676.
19. Kanda T, Yokosuka O, Imazeki F, Fujiwara K, Nagao K, and Saisho H: Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun 2005;331: 621-629.
20. Kanda T, Zhang B, Kusov Y, Yokosuka O, and Gauss-Muller V: Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. Biochem Biophys Res Commun 2005; 330:1217-1223.
21. Kato J, Kato N, Moriyama M, et al.: Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNAactivated protein kinase-independent pathway. J Infect Dis 2002;186:155-163.
22. Kiyohara T, Totsuka A, Yoneyama T, Ishii K, Ito T, and Wakita T: Characterization of anti-idotypic antibodies mimicking antibody-and receptor-binding sites on hepatitis A virus. Arch Virol 2009;154:1263-1269.
23. Komar AA, and Hatzoglou M: Internal ribosome entry sites in cellular mRNAs: mystery of their existence. J Biol Chem 2005;280:23425-23428.
24. Korf M, Jarczak D, Beger C, Manns MP, and Kruger M: Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 2005; 43:225-234.
25. Kotenko SV, Gallagher G, Baurin VV, et al.: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
26. Licursi M, Komatsu Y, Pongnopparat T, and Hirasawa K: Promotion of viral IRES-mediated translation under amino acid starvation. J Gen Virol 2012;93:951-962.
27. Li J, Lin S, Chen Q, et al.: Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol 2010;84:6387-6399.
28. Li Q, Kawamura K, Ma G, et al.: Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anticancer agents. Eur J Cancer 2010;46:180-190.
29. Ma D, Jiang D, Qing M, et al.: Antiviral effect of interferon lambda againstWest Nile virus. Antiviral Res 2009;83:53-60.
30. Mackiewicz V, Cammas A, Desbois D, et al.: Nucleotide variability and translation efficiency of the 5' untranslated region of hepatitis A virus: update from clinical isolates associated with mild and severe hepatitis. J Virol 2010;84: 10139-10147.
31. Martin A, and Lemon SM: Hepatitis A virus: from discovery to vaccines. Hepatology 2006;43:S164-S172.
32. Miyamura T, Ishii K, Kanda T, et al.: Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure. Hepatol Res 2011;42:248-253.
33. Miyamura T, Kanda T, Nakamoto S, et al.: Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 2011;6:e28617.
34. Mordstein M, Neugebauer E, Ditt V, et al.: Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010;84: 5670-5677.
35. Muir AJ, Shiffman ML, Zaman A, et al.: Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822-832.
36. Robek MD, Boyd BS, and Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79: 3851-3854.
37. Robertson BH, Jansen RW, Khanna B, et al.: Genetic relatedness of hepatitis A strains recovered from different geographical regions. J Gen Virol 1992;73:1365-1377.
38. Schultz DE, Honda M, Whetter LE, McKnight KL, and Lemon SM: Mutations within the 5' nontranslated RNA of cell culture-adapted hepatitis A virus which enhance capindependent translation in cultured African green monkey kidney cells. J Virol 1996;70:1041-1049.
39. Sheppard P, Kindsvogel W, Xu W, et al.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-68.
40. Shimazaki T, Honda M, Kaneko S, and Kobayashi K: Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein. Hepatology 2002;35:199-208.
41. Svetlikova D, Kabat P, Ohradanova A, Pastorek J, and Betakova T: Influenza A virus replication is inhibited in IFNlambda2 and IFN-lambda3 transfected or stimulated cells. Antiviral Res 2010;88:329-333.
42. Tanaka Y, Nishida N, Sugiyama M, et al.: Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
43. Wakita T, Pietschmann T, Kato T, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
44. Wu S, Kanda T, Imazeki F, et al.: Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol 2010;23:467-476.
45. Yang L, Kiyohara T, Kanda T, et al.: Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. Virol J 2010;7:212.
46. Yi M, Schultz DE, and Lemon SM: Functional significance of the interaction of hepatitis A virus RNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH): opposing effects of GAPDH and polypyrimidine tract binding protein on internal ribosome entry site function. J Virol 2000;74: 6459-6468.
47. Yu ML, Huang CF, Huang JF, et al.: Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011;53:7-13.
48. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, and Hartmann R: Type III interferon (IFN) induces a type I IFNlike response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007;81:7749-7758.
49. Zhu H, Butera M, Nelson DR, and Liu C: Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2005;2:80.